Reflections on ASCO (American Society of Clinical Oncologists).
As life expectancy increases and the population ages, people become more susceptible to degenerative diseases such as cancer. This has wide-ranging implications for cancer care, a specialty that has historically been underfunded and under-resourced in the UK. Dr. Martin Duerden, who canvassed the opinions of UK oncologists at the American Society of Clinical Oncologists' conference in Los Angeles earlier this year, focuses on the provision of chemotherapy in the context of the latest evidence and considers the implications for cancer care in a changing NHS.
Duerden
M
M
University of Liverpool.
D000368:Aged; D005260:Female; D006291:Health Policy / Q000191:economics; D006801:Humans; D015994:Incidence; D008017:Life Expectancy / Q000639:trends*; D008297:Male; D008495:Medical Oncology / Q000191:economics* / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D011157:Population Dynamics; D013222:State Medicine; D015996:Survival Rate; D006113:United Kingdom / Q000453:epidemiology; D014481:United States / Q000453:epidemiology